# A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects

> **NCT05399030** · PHASE1 · COMPLETED · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 72 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** ICP-332
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05399030
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-14
- **Primary completion:** 2022-01-30
- **Final completion:** 2022-02-18
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2022-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05399030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05399030, "A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05399030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*